SER-287
Ulcerative Colitis
Phase 2bCompleted
Key Facts
About Seres Therapeutics
Seres Therapeutics is a clinical-stage microbiome therapeutics company focused on revolutionizing patient care by harnessing the power of the human microbiome. The company achieved a landmark milestone with the FDA approval of VOWST™, the first orally administered microbiome therapeutic for preventing recurrent C. difficile infection. Seres continues to advance a diverse pipeline targeting significant unmet medical needs in infectious diseases, inflammatory bowel disease, and oncology through its proprietary microbiome platform and strategic collaborations.
View full company profileTherapeutic Areas
Other Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Mirikizumab | Eli Lilly | Phase 3 |
| Filgotinib | Gilead Sciences | Phase 3 |
| Obefazimod (ABX464) | Abivax | Phase 3 |
| Icotrokinra (JNJ-2113) | Protagonist Therapeutics | Phase 3 |
| DE-130 (Etrasimod) | Rohto Pharmaceutical | Phase 3 |
| DE-122 (Carotegrast methyl) | Rohto Pharmaceutical | Phase 3 |
| Methylene Blue MMX® | Cosmo Pharmaceuticals | Preclinical |
| KRP-203 (Amiselimod) | Kissei Pharmaceutical | Phase II |
| EVO301 | Evommune | Phase 1 |
| Pentasa (Mesalazine) | Zeria Pharmaceutical | Approved/Commercial |
| SER-301 | Seres Therapeutics | Phase 1b |
| IMP731 | Immutep | Phase 2 |